Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.

ABSTRACT:

Background

Literature is divided regarding the risk of neonatal ventricular septal defect (VSD) associated with first trimester ondansetron use in pregnancy.

Methods

We evaluated the risk of VSD associated with first trimester exposure to intravenous or oral ondansetron in 33 677 deliveries at Magee-Womens Hospital in Pittsburgh, PA (2006-2014). Using log-binomial regression, we evaluated the risk: (1) in the full cohort, (2) using propensity score designs with both matching and inverse probability weighting and (3) utilizing clustered trajectory analysis evaluating the role of dose. Sensitivity analyses assessed the association between ondansetron and all recorded birth defects in aggregate.

Results

A total of 3733 (11%) pregnancies were exposed to ondansetron in the

SUBMITTER: Lemon LS 

PROVIDER: S-EPMC7266534 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature